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Abstract
Background:  The mechanisms by which alpha-2 adrenergic receptors are down-regulated
following chronic exposure to agonist are not well understood. Interestingly, the human alpha-2C
receptor does not down-regulate, whereas the opossum alpha-2C receptor does down-regulate.
A comparison of the amino acid sequence of the third intracellular loop of these two receptors
shows that the opossum alpha-2C receptor contains a potential G protein-coupled receptor kinase
(GRK)phosphorylation motif (EESSTSE) with four hydroxyl residues, whereas the human alpha-2C
receptor motif only contains two hydroxyl residues (DESSAAAAE). Because a similar acidic serine-
rich motif (EESSSSD) in the human alpha-2 adrenergic receptor has been demonstrated to be
phosphorylated by GRK and all four serines are required for desensitization of the receptor, we
sought to determine whether the EESSTSE sequence was involved in the down-regulation of the
alpha-2C adrenergic receptor.
Results: Site-directed mutagenesis was used to mutate the opossum alpha-2C receptor to SSVA
and AAVA in place of the SSTS wild-type sequence. Down-regulation experiments on CHO cells
transfected with the receptors demonstrated that neither of the mutated receptors down-
regulated following 24 h exposure to norepinephrine, whereas the wild-type receptor down-
regulated to 65 ± 10% of the control.
Conclusions: These results indicate that a motif with four hydroxyl amino acid residues in an
acidic environment is important for down-regulation of the opossum alpha-2C adrenergic
receptor. Because these are potential GRK phosphorylation sites, we suggest that GRK
phosphorylation may be involved in alpha-2C adrenergic receptor down-regulation.
Background
Prolonged or repeated agonist stimulation of G protein-
coupled receptors frequently causes a reduction in the re-
sponse to the agonist [1]. Short-term agonist exposure re-
sults in desensitization that is characterized by a rapid
(minutes) and reversible uncoupling of the receptor from
the G protein followed by sequestration and/or internali-
zation of receptors from the cell surface. Down-regulation
occurs after prolonged agonist treatment (hours to days),
resulting in a loss of receptor binding sites [2–4]. The
processes involved in homologous desensitization have
been extensively investigated for the beta-2 adrenergic re-
ceptor, which is the prototypical G protein-coupled recep-
tor. Initial uncoupling of the beta-2 receptor from the G
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protein after agonist binding is mediated by phosphoryla-
tion by G protein-coupled receptor kinase (GRK) of spe-
cific residues in the carboxyl tail of the receptor. The
phosphorylated beta-2 receptor enhances the binding of
beta-arrestin, which not only uncouples the receptor from
the signal transduction process but also serves as an adapt-
er protein that mediates entry into the internalization
pathway [5], as well as serving as a platform for additional
signaling pathways [6]. The mechanisms of beta-2 adren-
ergic receptor down-regulation appear to involve both an
increase in the rate of degradation of the receptor as well
as a decrease in the levels of beta receptor mRNA [7].
Down-regulation of the beta-2 receptor is, in part, due to
trafficking of the beta-2 receptor to lysosomes via the
clathrin-coated pit endosomal pathway [8,9].
The alpha-2 adrenergic receptors also undergo agonist-in-
duced desensitization and down-regulation. Desensitiza-
tion occurs both in cell culture systems [10–12] and in the
intact animal [13,14]. In general the mechanisms of de-
sensitization for the alpha-2 adrenergic receptors appear
to be similar to those for the beta-2 receptor. There are
three subtypes of the alpha-2 adrenergic receptor: alpha-
2A; alpha-2B; and alpha-2C [15]. The human alpha-2A
subtype undergoes phosphorylation and short-term de-
sensitization [11,12], whereas the human alpha-2C sub-
type is not phosphorylated [16] and does not desensitize
[11]. The human alpha-2C subtype, however, does under-
go arrestin-dependent internalization [17]. Many studies
[11,18], including those from our laboratory [10,19,20],
have demonstrated agonist-induced down-regulation of
alpha-2 receptors, although much less is known about the
specific mechanisms for down-regulation as compared to
the beta-2 receptor. In contrast to alpha-2A and alpha-2B
adrenergic receptors from several species, the human al-
pha-2C receptor does not appear to down-regulate in re-
sponse to agonist treatment in transfected cell culture
systems [11]. By contrast, the opossum alpha-2C receptor
in the OK cell line does down-regulate in response to
norepinephrine [19,20]. The reason for this difference is
the focus of the current studies.
The human alpha-2A adrenergic receptor has an acidic
serine-rich motif (EESSSSD) in the third intracellular loop
that has been shown to be important in agonist-induced
desensitization but not in agonist-induced sequestration/
internalization. Site-directed mutagenesis studies indicate
that all four of these serines are phosphorylated by GRK,
and all four are needed for desensitization [12]. The influ-
ence of this motif on down-regulation was not investigat-
ed, however. The opossum alpha-2C adrenergic receptor
has a very similar acidic serine motif (EESSTSE) in the
third intracellular loop (Figure 1; [21]), whereas the hu-
man alpha-2C receptor has a DESSAAAE sequence in the
same region (Figure 2; [22]). Thus, we postulated that the
lack of down-regulation in the human alpha-2C was relat-
ed to having only two rather than four serines in the mo-
tif, and furthermore that the ability of the opossum alpha-
2C to undergo down-regulation was dependent on having
all four serine/threonine residues in the EESSTSE motif.
To test this hypothesis, we mutated the opossum alpha-
2C serines and threonine residues to alanines and valine,
respectively, and tested whether the expressed receptors
would down-regulate. Down-regulation was not observed
in the mutated receptors following treatment with nore-
pinephrine for 24 h.
Results
Sequence of the opossum alpha-2C adrenergic receptor
In the process of confirming the mutations, we also com-
pletely re-sequenced the wild-type clone and found sever-
al differences from the originally published sequence
(GenBank #U04310 [21]). The corrected sequence differs
from the original in 19 bases, which results in 11 amino
acid residue changes as detailed in Figure 2. The sequence
has been corrected in Genbank.
Characterization of mutated receptors
The results of [3H]rauwolscine saturation experiments us-
ing the wild-type and mutated receptors from two inde-
pendent transfections of both mutations are given in
Table 1. The Kd values for the two mutants (0.071–0.118
nM) were similar to those of the wild-type (0.113 nM)
and similar to the previously reported Kd of 0.056 nM for
the wild-type alpha-2 receptor for [3H]rauwolscine in
NaPO4 buffer [23]. Inhibition experiments with [3H]rau-
Figure 1
The sequence of the third intracellular loop of the opossum
alpha-2C adrenergic receptor. The sequence of the two
mutated receptors created by site-directed mutagenesis are
indicated. Potential phosphorylation sites (serine and threo-
nine residues) are shown in red.
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Figure 2
Comparison of the sequences for human and opossum alpha-2 adrenergic receptors. Differences between the original and the
revised opossum alpha-2C sequences are shown in green. Differences between the human and the revised opossum alpha-2C
sequence are shown in blue. The transmembrane regions are shown as a line over the sequence. The EESSTSE sequence is
identified with a box.
            1                                             50
OK Revised  ~~~~~~~~~~ ~MDLQLTTNS TDSGDR..GG SSNES.LQRQ PP.SQYSPAE 
OK Original ~~~~~~~~~~ ~MDLQLTTNS TDSGDR..GG SSNES.LQRQ PP.SQYSPAE 
Human    MASPALAAAL  AVAAAAGP NA SGAGERGSGG VANASGASWG PPRGQYSAGA 
            51          I                                 II   100
OK Revised  VAGLAAVVSF LIVFTIVGNV LVVIAVLTSR ALKAPQNLFQ VSLASADILV 
OK Original VAGLAAVVSF LIVFTIVGNV LVVIPVLTSR ALKAPQNLFL VSLASADILV 
Human       VAGLAAVVGF LIVFTVVGNV LVVIAVLTSR ALRAPQNLFL VSLASADILV 
            101                                   III           150
OK Revised  ATLVMPFSLA NELMNYWYFG KVWCVIYLAL DVLFCTSSIV HLCAISLDRY 
OK Original ATLVMPFSLA NELMNYWYFG KVWCDIYLAL DVLFCTSSIV HLCAISLDRY 
Human  ATLVMPFSLA NELMAYWYFG QVWCGVYLAL DVLFCTSSIV HLCAISLDRY 
            151                            IV                   200
OK Revised  WSVTQAVEYN LKRTPRRIKG IIVTVWLISA VISFPPLISL YRDPEDDLYP 
OK Original WSVTQAVGYN LKRTPRRIKG IIVTVWLISA VISFPPLISL YRDPEDDLYP 
Human WSVTQAVEYN  LKRTPRRVKA TIVAVWLISA VISFPPLVSL YRQPDGAAYP 
            201              V                                 250
OK Revised  QCELNDETWY ILSSCIGSFF APCIIMVLVY VRIYRVAKLR TRTLSEKRTV 
OK Original QCELNDETWY ILSSCIGSFF APCIIMVLVY VRIYRVAKLR TRTLSEKRTV 
Human  QCGLNDETWY ILSSCIGSFF APCLIMGLVY ARIYRVAKLR TRTLSEKR.A 
            251                                                300
OK Revised  PEGSSQTENG LSRPPVGAGP STAAAAAASL RLQAGENGHY HLHHHHHHLH 
OK Original PEGSSQTENG LSRPPVGAGP STAAAAAASL RLQAGENGHY HLHHHHHHLH 
Human  PVG....... ....PDGASP TTENGLGAA. .AGAGENGHC .......... 
            301                                                350
OK Revised  HHHHHHHHQL RKSAELEDIE LEESSTSENR RRRR...... SREEAAARKG 
OK Original HHHHHHHHQL RKSAELEDIE LEESSTSENR RRRR...... SREEAARPKG 
Human  .......... ..APPPADVE PDESSAAAER RRRRGALRRG GRRRAGAEGG 
            351                                                400
OK Revised  SRGF...... ..SFSFSSTK GGQSAGAGSR LSRASNRSLE FFSTHRRRKR 
OK Original RPRF...... ..SFSFSSTK GGQSAGAGSR LSRASNRSLE FFSSHRRRKR 
Human  AGGADGQGAG  PGAAESGALT  ASRSPGPGGR LSRASSRSVE FFLSRRRRAR 
            401                             VI                  450
OK Revised  SSLCRRKVTQ AREKRFTFVL AVVMGVFVVC WFPFFFTYSL YGICREACQV 
OK Original SSLCRRKVTQ AREKRFTFVL AVVMGVFVVC WFPFFFTYSL YGICREACQV 
Human  SSVCRRKVAQ AREKRFTFVL AVVMGVFVLC WFPFFFSYSL YGICREACQV 
            451            VII                               498
OK Revised  PETLFKFFFW IGYCNSSLNP VIYTIFNQDF RRSFKHILFK KKKKTSLQ 
OK Original PETLFKFFFW FGYCNSSLNP VIYTIFNQDF RRSFKHILFK KKKKTSLQ 
Human  PGPLFKFFFW IGYCNSSLNP VIYTVFNQDF RRSFKHILFR RRRRGFRQ BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/9
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wolscine indicated that the affinity of norepinephrine for
the mutated receptors was approximately two-fold higher
(lower Kd value) than for wild-type receptor (Figure 3).
Down-regulation
After a 24 h treatment with 0.3 µM norepinephrine, the
wild-type receptor down-regulated to 65 ± 10 % of control
(p < 0.05; n = 7). By contrast, no down-regulation was ob-
served with either the SSVA (114 ± 10 % of control) or the
AAVA (110 ± 9 % of control) receptors (Figure 4).
Discussion
All three alpha-2 adrenergic receptor subtypes from nearly
all species that have been tested undergo agonist-induced
down-regulation [24,25]. Interestingly, we have shown
that the potency of norepinephrine to produce down-reg-
ulation differs among alpha-2 receptor subtypes [19,24].
The concentration of norepinephrine required to produce
half-maximal down-regulation is approximately 2 µM for
the alpha-2A receptor. In contrast, norepinephrine is
more potent at down-regulating the alpha-2B and alpha-
2C subtypes, with a concentration of only 70 nM required
to produce half-maximal down-regulation. This difference
in potency appears to be a characteristic of the receptor
protein itself, because the cellular environment in which
a particular subtype is expressed does not affect the poten-
cy of norepinephrine to produce down-regulation.
The human alpha-2C receptor is somewhat unique
among the alpha-2 receptors in that it does not appear to
undergo agonist-induced down-regulation [11]. The hu-
man alpha-2A adrenergic receptor, which does undergo
down-regulation, has an acidic serine motif (EESSSSD) in
the third intracellular loop. Sequentially mutating each of
the four serines to alanine decreased the phosphorylation
of the receptor by approximately 25% for each serine, and
mutating either the first two or the last two serines to
alanines prevented agonist-induced desensitization, but
not agonist-induced sequestration/internalization [12].
The influence of mutations in this motif on down-regula-
tion has not been investigated. The human alpha-2C re-
ceptor, by contrast, has a DESSAAAE sequence in the same
region [Figure 2; [22]]. Thus, it is possible that the lack of
desensitization and perhaps also down-regulation of the
human alpha-2C receptor is due to the fact that there are
only two hydroxyl residues in the DESSAAAE motif rather
than the four hydroxyl residues in the alpha-2A EESSSSD
motif.
Table 1: Affinity (Kd) and density (Bmax) of mutated alpha-2C 
adrenergic receptors expressed in CHO cells.
Clone Kd, nM Bmax, fmol/mg protein n
Wild-type (SSTS) 0.113 ± 0.008 372 ± 81 7
SSVA clone #1 0.105 ± 0.005 357 ± 103 3
SSVA clone #2 0.088 ± 0.009 90 ± 31 4
AAVA clone #1 0.118 ± 0.012 327 ± 105 3
AAVA clone #2 0.071 ± 0.009 39 ± 18 4
The Kd and Bmax values are geometric and arithmetic means respec-
tively from nonlinear regression analysis of saturation experiments 
with over a 100-fold concentration range of [3H]rauwolscine. Clone 
#1 and #2 were from separate transfections
Table 2: Affinity of norepinephrine for the mutated alpha-2C 
adrenergic receptors expressed in CHO cells.
Clone Ki, nM Slope factor n
Wild-type (SSTS) 184 ± 90 . 7 9 3
SSVA 90 ± 4* 0.73 3
AAVA 71 ± 5* 0.65 3
Ki values were derived based on a single-site model and are the geo-
metric means of three independent inhibition experiments, each done 
in duplicate. The slope factor was determined in a separate analysis 
based on a variable slope model. The data were not consistently bet-
ter fit by a two-site model than a one-site model for any of the three 
clones. The concentration of [3H]rauwolscine was 0.12 ± 0.01 nM. 
*Significantly different (p < 0.05) than wild-type based on a t-test of 
the pKi values.
Figure 3
Norepinephrine inhibition of [3H]rauwolscine binding. The
data points are the means ± SEM of three independent inhibi-
tion experiments, each done in duplicate. The concentration
of [3H]rauwolscine was 0.12 ± 0.01 pM. The IC50 values
determined from these data are 380 nM, 170 nM and 160 nM
for the wild-type (SSTS), SSVA and AAVA receptors, respec-
tively. The 100% values were 1223, 755 and 285 cpm for the
wild-type (SSTS), SSVA and AAVA mutants, respectively. The
means of the Ki values determined in the three individual
experiments are given in Table 2.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/9
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The opossum alpha-2C adrenergic receptor has a EESSTSE
acidic serine/threonine motif in the third intracellular
loop (Figures 1 and 2), which could be a substrate for GRK
based on the EESSSSD motif of the alpha-2A subtype.
Thus, we postulated that the lack of down-regulation in
the human alpha-2C subtype is related to having only two
rather than four serines in the motif, and that mutating
the threonine and serine residues at the end of the opos-
sum EESSTSE motif to valine and alanine residues to give
EESSVAE might prevent down-regulation of the opossum
alpha-2C receptor. Consistent with this prediction, treat-
ment with 0.3 µM norepinephrine for 24 h failed to
down-regulate the receptor containing the motif mutated
to EESSVAE, although the wild-type receptor with the
EESSTSE motif was down-regulated by 35%.
The inhibition data indicate that the affinity of norepine-
phrine for the receptors containing the mutations is
slightly higher than for the wild-type. The affinity of nore-
pinephrine for the mutated receptor lacking two of the hy-
droxyl residues was approximately twice as high as the
wild-type. The elimination of the remaining two hydroxyl
residues did not have any additional effect on the affinity
of norepinephrine. These data eliminate the possibility
that the lack of down-regulation in cells containing the
mutated receptors is a consequence of the mutants having
a lower affinity for norepinephrine than the wild-type.
The elimination of the terminal two hydroxyl amino acid
residues in the EESSTSE motif is sufficient to prevent
down-regulation of the opossum alpha-2C adrenergic re-
ceptor. Similarly, mutation of only two serine residues in
the human alpha-2A receptor resulted in a loss of desensi-
tization [12]. Because the EESSSSE motif in the human al-
pha-2A receptor is a known GRK substrate, and because
eliminating two potential phosphorylation sites prevents
down-reguation, phosphorylation of the opossum alpha-
2C receptor may be important in the mechanism of
down-regulation of this receptor. By contrast, a deletion
of twelve residues of the human alpha-2A receptor (293–
304) which includes the EESSSSE motif did not appear to
prevent agonist-induced down-regulation [26]. Thus a
phosphorylation pathway may not be involved in agonist-
induced down-regulation of the alpha-2A adrenergic re-
ceptor.
In addition to the hydroxyl amino acid residues, acidic
residues may also be an important sequence element for
alpha-2 adrenergic receptor phosphorylation and regula-
tion [27,28]. The region from 300 to 313 in the opossum
alpha-2C receptor, which encompasses the EESSTSE mo-
tif, is a high acidic region, with 50% (seven of fourteen) of
the residues being acidic amino acids (Figure 2). In an ef-
fort to determine if four hydroxyl amino acid residues in
an acidic environment might be a common motif for
phosphorylation and receptor regulation, we searched the
G Protein-Coupled Receptor Database for four consecu-
tive hydroxyl residues (either serine or threonine) in a lin-
ear sequence that was at least 1/3 acidic with no basic
residues which occurred in either the third intracellular
loop or the carboxyl terminal tail. As can be seen from the
results in Table 3, this does not appear to be a common
motif for G protein-coupled receptors, not even for alpha-
2 adrenergic receptors. Indeed, this motif is not found in
the alpha-2B subtype which does undergo agonist-in-
duced down-regulation, although as noted above a highly
acidic region appears to be important and could be related
to the additional negative charge provided by phosphor-
ylation. Thus, it is likely that there are multiple mecha-
nisms that are involved in down-regulation of G protein-
coupled receptors.
Conclusions
A motif with four hydroxyl amino acid residues in an acid-
ic environment appears to be important for down-regula-
tion of the alpha-2C adrenergic receptor. The human
alpha-2C receptor, which has a DESSAAAE motif with
only two hydroxyl residues, does not undergo down-regu-
Figure 4
Effect of 24 h treatment with norepinephrine on binding of
[3H]rauwolscine. Cell were incubated with 0.3 µM norepine-
phrine or vehicle for 24 h and membranes prepared. Specific
binding to the alpha-2C adrenergic receptor was determined
using 0.40 nM [3H]rauwolscine. The values are mean ± SEM
for 7 experiments using two different clones. Each experi-
ment consisted of three culture dishes with norepinephrine
and three without norepinephrine for each clone and each
dish was assayed in duplicate. The amount of specific binding
in the wild-type following the norepinephrine pretreatment
was significantly different from the binding in the control by a
t-test (p < 0.05). The binding levels of the two mutant clones
were not different following norepinephrine pretreatment as
compared to control.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/9
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lation. Modification of the EESSTSE to EESSVAE was suf-
ficient to prevent down-regulation of the opossum alpha-
2C adrenergic receptor. Because these are potential GRK
phosphorylation sites, our data further suggest that GRK
phosphorylation may be involved in down-regulation of
the alpha-2C adrenergic receptor.
Materials and Methods
Materials
Restriction enzymes were purchased from New England
Biolabs (Boston, MA). Norepinephrine and other chemi-
cals were from Sigma (St. Louis, MO).
Site-directed mutagenesis
Mutations of the opossum alpha-2C adrenergic receptor
cDNA in pRc/CMV vector described previously [21] was
accomplished using the QuickChange™ Site Directed Mu-
tagenesis Kit (Stratagene, LaJolla, CA). The SSTS sequence
in the third cytoplasmic loop (amino acid residues 309–
312; Figures 1 and 2) was mutated to SSVA using forward
and reverse primers with the following sequences (the
bases introducing the mutation are underlined), which
also introduced a new restriction site:
GAACTGGAGGAGAGTAGCGTGGCTGAGAACCGGCG-
CAGGAGGC and GCCTCCTGCGCCGGTTCTCAGC-
CACGCTACTCTCCTCCAGTTC, respectively. To screen for
the presence of the mutation, the alpha-2 adrenergic re-
ceptor insert was cut from the vector using Hind III (895)
and EcoR1 (1841) and cut with Ddel. In a similar manner
a further AAVA mutation was prepared from SSVA using
GACATCGAACTGGAGGAGGCCGCAGTGGCTGAGAAC-
CGGCGC and GCGCCGGTTCTCAGCCACTGCGGCCTC-
CTCCAGTTCGATGTC forward and reverse primers,
respectively. The presence of the second mutation was de-
termined using the AlwNi. To further confirm the se-
quence, the entire cDNA for the insert was sequenced for
each mutation.
Cell culture
CHO-K1 cells (American Type Culture Collection) were
maintained in Ham's F-12 medium (GIBCO) with 10%
fetal bovine serum (GIBCO 26140-079) in 95 % air/5%
CO2 at 37°C in a humid atmosphere. Wild-type and mu-
tated receptors in the pRc/CMW vector were transfected
into CHO-K1 cells using calcium phosphate precipitation
technique as described previously [21]. Stable transfect-
ants were selected with 500 µg/ml G-418 (Geneticin; Life
Technologies) and screened by intact cell binding using
[3H]rauwolscine as previously described [21].
Down-regulation assays
The cells were plated at a density of 2 ×  105 cells/ml in
150-mm culture dishes with 20 ml of growth media and
allowed to grow for four days to near confluence. The me-
dium was replaced with fresh medium lacking G-418.
Twenty-four hours later, either 2 µl of 3 mM norepine-
phrine in 5 mM HCl or just 2 µl of 5 mM HCl (vehicle
control) was added to each of the plates. Cells were har-
vested 24 h after adding norepinephrine or vehicle. The
medium was removed and the cells were rinsed with 10
ml of cold phosphate-buffered saline (PBS) containing 5
mM EGTA, pH 7.4. Another 10 ml of PBS was added to the
plate and the cells were scraped off the plate using a rub-
ber policeman. The plate was rinsed once with 10 ml of
PBS. The scraped cells were centrifuged at 2000 ×  g for 5
min at 4°C, the supernatant was discarded, and the pellet
was stored at -80°C until assayed. We used 300 nM nore-
pinephrine in the down-regulation studies because we
have previously shown that this concentration induces
maximal down-regulation for the wild-type alpha-2C sub-
type [20,24].
Table 3: G protein-coupled receptors with four hydroxyl amino acid residues in a acid environment. 
Receptor Species Sequence % acidic Location
Alpha-2C opossum      ELEDIELEESSTSE5 0 3 rd Loop
Alpha-2A multiple       DLEESSSSE4 4 3 rd Loop
Dopamine insect       TTTSTPEEPDDE 42 3rd Loop
Rhodopsin pig    DDEASTTTS 33 C terminus
Rhodopsin arthopod    ESDDVSESASTTTSAEE 33 C terminus
Rhodopsin vertebrate      EEDEASTSS 44 C terminus
Rhodopsin vertebrate      DEDEESTSS 56 C terminus
Rhodopsin vertebrate      DDEEASSSS 44 C terminus
cAMP class E Dictyostelium        DEGSSSSSLSSSDEE 33 C terminus
The G Protein-Coupled Receptor Database  [http://www.gpcr.org/]  was searched for four consecutive hydroxyl amino acid residues (either serine 
or threonine) in a linear sequence that was at least 1/3 acidic (aspartic or glutamic) with no basic residues (lysine or arginine) and which occurred in 
either the third intracellular loop or the carboxyl-terminal tail.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/9
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Radioligand Binding
Pellets were homogenized in 12 ml of ice-cold 50 mM Tris
HCl buffer (pH 8.0) with a Tissumizer (Tekmar, Cincinna-
ti, OH) for 20 sec at 75% of the maximum speed and the
suspension was centrifuged at 47,000 ×  g for 10 min at
4°C. This step was repeated a second time. For saturation
experiments, the resulting pellet (a crude particulate
membrane fraction) was resuspended in 200 volumes of
25 mM NaPO4 buffer (pH 7.4) and re-homogenized for
use in the radioligand binding assay. For down-regulation
experiments the cells were re-homogenized in 5 ml of 25
mM NaPO4 buffer (pH 7.4).
For saturation experiments, duplicate tubes were prepared
containing 970 µl of tissue and 20 µl of [3H]rauwolscine
at six concentrations, with final concentrations from ap-
proximately 6 pM to 0.6 nM. Nonspecific binding was de-
termined using a final concentration of 200 µM (-)-
norepinephrine. For competition experiments, duplicate
tubes were prepared containing 970 µl of tissue, 10 µl of
norepinephrine at various concentrations, and 20 µl of
[3H]rauwolscine (81.5 Ci/mmol, NEN-Dupont, Boston,
MA) at a single concentration of 0.12 nM, which is ap-
proximately the Kd value. Twelve appropriately spaced
concentrations of norepinephrine were used in each com-
petition experiment. The extent of down-regulation was
determined using a single concentration of [3H]rauwols-
cine (0.40 nM; about 3 times the Kd value). We have pre-
viously shown that norepinephrine pretreatment does not
alter the radioligand Kd of the opossum alpha-2C adren-
ergic receptor [20,24], thus making it possible to estimate
the receptor density with a single concentration of radio-
ligand. Total binding was determined in triplicate and
nonspecific binding in duplicate for each of the three
dishes for each condition. All assays were incubated at
room temperature for 60 min. Membrane suspensions
were filtered through Whatman GF/B glass fiber filters
with a 48-sample Brandel cell harvester (Biomedical Re-
search and Development, Gaithersburg, MD). Filters and
tubes were washed three times with ice-cold 50 mM Tris
HCl buffer (pH 8.0). Radioactivity was determined by liq-
uid scintillation photometry. Protein concentrations were
determined using the Bio-Rad Protein Assay (Bio-Rad,
CA) based on the Bradford method [29], with bovine se-
rum albumin as the standard.
Data analysis
Bmax (receptor density) and Kd (radioligand affinity) val-
ues were determined from the analyses of saturation ex-
periments utilizing nonlinear regression with Prism 3
(GraphPad, San Diego, CA). Bmax and Kd values are given
as arithmetic and geometric means, respectively. Compe-
tition binding data were also analyzed with Prism 3 to de-
termine the IC50 values based on the single-site model
and slope based on the variable slope model. Ki values
were calculated from the IC50 values [30], and are present-
ed as geometric means. The statistical analysis of the
down-regulation data was conducted using a two-tailed
paired t-test of the mean of the duplicate assays for each
dish of cells incubated in the presence of norepinephrine
as compared to control cells.
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